Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Prognostic evaluation of ELN-2022 and ELN-2024 risk stratification in newly diagnosed AML patients and development of a novel genetic risk model

View Full Paper
Ask AI
Bookmark
Share

Authors

GYGuangyue YaoMZMinran Zhou

Discussion

Loading...

Member takes

Overview

Retrospective analysis identifies genetic risk model impacting overall survival and progression-free survival in AML, suggesting improved prognostic strategies.

Key Points

  • Genetic risk model significantly influences overall survival and progression-free survival in acute myeloid leukemia patients.
  • The area under the curve for the new model was improved compared to existing strategies, demonstrating enhanced predictive performance.
  • A cohort of 428 adult patients was analyzed, with key genetic factors such as TP53 and DNMT3A identified as important prognostic determinants.
  • ELN-2022 risk stratification was notably effective only for intensive chemotherapy, underlining the need for tailored approaches in AML treatment.

Cite This Study

Yao et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3d1https://doi.org/10.1182/blood-2025-5269
View Full Paper
Ask AI
Bookmark
Share